Table 1.
Details of vaccines against SARS-CoV2 and its approval and dosing count in India.
| Vaccine generic | Brands | Type of vaccine | Manufacturer | Status in India |
|---|---|---|---|---|
| AZD1222 (ChAdOx1) | COVID-19 Vaccine AstraZeneca, Covishield, Vaxzevria | Adenovirus vaccine | BARDA, OWS, Serum Institute of India | Approved in India, Total vaccine doses administered as on 26/03/22 is 1,50,80,58,152 |
| BBV152 | Covaxin | Inactivated vaccine | Bharat Biotech, ICMR; Ocugen; ViroVax | Approved in India, Total vaccine doses administered as on 26/03/22 is 30,52,68,845 |
| rAd26 and rAd5 | Sputnik V | Recombinant adenovirus vaccine | Gamaleya Research Institute, Acellena Contract Drug Research and Development | Approved in India, Total vaccine doses administered as on 26/03/22 is 12,21,106 |
| Corbevax | Corbevax | Adjuvanted protein subunit vaccine | Biological E, Baylor College of Medicine, Dynavax, CEPI | Approved in India, Total vaccine doses administered as on 26/03/22 is 1,20,88,254 |
| BNT162b2 | COMIRNATY | mRNA-based vaccine | Pfizer, BioNTech, Fosun Pharma | Approved in India |
| ZyCoV-D | ZyCoV-D | DNA vaccine (plasmid) | Zydus Cadila | Approved in India |
| mRNA-1273 | Spikevax | mRNA-based vaccine | Moderna, BARDA, NIAID | Approved in India |
| rAd26 | Sputnik Light | Recombinant adenovirus vaccine | Gamaleya Research Institute, Acellena Contract Drug Research and Development | Approved in India |
| NVX-CoV2373 | Covovax (India), TAK-019(Japan) Nuvaxovid, |
Prefusion protein recombinant nanoparticle vaccine | Novavax; CEPI, Serum Institute of India | Approved in India |
| Sinopharm COVID-19 Vaccine (BBIBP-CorV) | BBIBP-CorV/NVSI-06–07 | Inactivated vaccine | Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | |
| EpiVacCorona/ (Aurora-CoV) | EpiVacCorona | Peptide vaccine | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | |
| JNJ-78436735; Ad26.COV2.S | Janssen | Non-replicating viral vector | Janssen Vaccines (Johnson & Johnson) | |
| CoviVac | CoviVac | Inactivated vaccine | Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products | |
| ZIFIVAX | ZF2001 | Recombinant vaccine | Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences | |
| QazCovid-in | QazVac | Inactivated vaccine | Research Institute for Biological Safety Problems | |
| CoronaVac (formerly PiCoVacc) | CoronaVac | formalin-inactivated and alum-adjuvanted vaccine | Sinovac | |
| Convidicea (Ad5-nCoV) | Ad5-nCoV /PakVac | Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics | |
| WIBP-CorV | WIBP-CorV | Inactivated vaccine | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | |
| COVIran Barekat | COVIran Barekat | Inactivated vaccine | Shifa Pharmed Industrial Group | |
| CIGB 66 | Abdala | Protein subunit vaccine | Center for Genetic Engineering and Biotechnology | |
| Soberana 02/Soberana Plus | Soberana 02/Soberana Plus | Conjugate vaccine | Finlay Institute of Vaccines; Pasteur Institute | |
| MVC-COV1901 | MVC-COV1901 | Protein subunit vaccine | Medigen Vaccine Biologics Corp.; Dynavax | |
| COVAX-19 | Spikogen | Monovalent recombinant protein vaccine | Vaxine Pty ltd.; CinnaGen | |
| FAKHRAVAC (MIVAC) | FAKHRAVAC (MIVAC) | Inactivated vaccine | The Stem Cell Technology Research Center; Organization of Defensive Innovation and Research | |
| Turkovac (ERUCOV-VAC) | Turkovac (ERUCOV-VAC) | Inactivated vaccine | Health Institutes of Turkey | |
| Covifenz (CoVLP) | Covifenz (CoVLP) | Plant-based adjuvant vaccine | Medicago; GSK; Dynavax | |
| VLA2001 | Valneva;UK National Institute for Health Research; Dynavax | Inactivated vaccine | France, United States | |
| Noora | Noora | Recombinant protein vaccine | Baqiyatallah University of Medical Sciences |
As per government of India database (Co-WIN), till 28th February 2022, a total of 1,48,26,49,754 doses of AstraZeneca, Covishield (ChAdOx-1) and 28, 80, 80,355 doses of COVAXIN (BBV152) was administered.